PacBio received $48.1 million in net cash proceeds from the transaction. Under the terms of the agreement, Illumina assumed certain liabilities and granted a non-exclusive license certain intellectual ...

PacBio announced a key study published in the American Journal of Human Genetics by Radboud University Medical Center, showcasing the effectiveness of its HiFi long-read sequencing technology for ...

MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration ...

MENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of a study published in ...

PacBio announced its involvement in a groundbreaking study published in Nature Genetics, which utilized its advanced sequencing technology to explore the genetic basis of a rare Mendelian condition in ...

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University ...

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

Long-read genome sequencing is being integrated early into ASO therapy development to capture complex genetic variants missed ...

About Pacific Biosciences PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical ...

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve ...